Implementation of endometrial cancer molecular subtyping into a hybrid community-academic practice.
Elizabeth O FerreiraAlexandra M SchefterAbby BrustadMolly E KleinMahmoud A KhalifaBoris WinterhoffAndrew Cook NelsonPublished in: American journal of clinical pathology (2024)
Our protocol identified 22 (14%) of 157 LR tumors that harbored incipient intermediate- to high-risk molecular aberrations in TP53, CTNNB1, or L1CAM. Moving forward, results of ongoing trials assessing adjuvant therapy decisions based on molecular classification are necessary to confirm protocol utility and identify appropriate modifications.